8-K 1 a05-13053_28k.htm 8-K

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported)   August 3, 2005

 

Tapestry Pharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)

 

Delaware

0-24320

84-1187753

(State or other jurisdiction

(Commission

(IRS Employer

of incorporation)

File Number)

Identification No.)

 

4840 Pearl East Circle, Suite 300W

Boulder, Colorado 80301

(Address of principal executive offices and zip code)

 

(303) 516-8500

Registrant’s telephone number, including area code

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

o  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

o  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

o  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

o  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 


 

Item 2.02. Results of Operations and Financial Condition.

 

On August 3, 2005, Tapestry Pharmaceuticals, Inc. issued a press release announcing its earnings for the second quarter of 2005. A copy of the press release is attached as Exhibit 99.1.

 

Item 9.01. Financial Statements and Exhibits.

 

(c)

 

Exhibits.

 

Exhibit No.

 

Description 

99.1

 

Press release dated August 3, 2005 issued by Tapestry Pharmaceuticals, Inc.

 

The information in this Form 8-K and the Exhibit attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, except as shall be expressly set forth by specific reference in such filing.

 

2


 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Dated: August 3, 2005

 

 

 

TAPESTRY PHARMACEUTICALS, INC.

 

 

 

 

 

By:

/s/  GORDON LINK

 

 

 

Gordon Link

 

 

 

Senior Vice President, Chief Financial Officer

 

3